Factual and Procedural Background
The Respondent discovered that the racemic antidepressant “citalopram” consists of two mirror-image molecules (enantiomers). After developing a method to separate them, the Respondent found that the (+) enantiomer (escitalopram) possessed the therapeutic benefit, whereas the (-) enantiomer diminished that effect. A European patent claiming: (i) the isolated (+) enantiomer (product claims) and (ii) the specific “diol” resolution process (process claim) was granted with a 1988 priority date.
The Appellants, all generic manufacturers, sought revocation of the patent in the United Kingdom. Before the trial judge (Judge Kitchin), lack-of-novelty and obviousness failed, but the main product claims were revoked for insufficiency. The Court of Appeal (Judge Hoffmann, Judge Smith and Judge Jacob) reversed on that point and upheld the patent. The Appellants appealed to the final appellate court, which delivered the opinion excerpted above.
Legal Issues Presented
- Whether product claims to the isolated (+) enantiomer are invalid for insufficiency where the specification discloses only one inventive method of manufacture but later, independent methods become available.
- (Raised below but not pursued on the final appeal) Whether the product claims lacked novelty or were obvious in light of the prior racemate disclosure.
Arguments of the Parties
Appellants' Arguments
- The patent’s technical contribution lies solely in the disclosed “diol” resolution process; therefore product claims covering all ways of making the (+) enantiomer are unsupported and insufficient.
- Following Biogen Inc v Medeva Plc, the patent monopoly must not extend beyond the inventive step; the Respondent should receive protection only for the disclosed process, not the product itself.
Respondent's Arguments
- Once novelty and inventive step are established for the product, the technical contribution is the product; sufficiency is satisfied because the specification enables the skilled person to make the product.
- European Patent Office (EPO) jurisprudence consistently upholds product claims in identical circumstances; United Kingdom law should align with that approach.
Table of Precedents Cited
| Precedent |
Rule or Principle Cited For |
Application by the Court |
| Biogen Inc v Medeva Plc [1997] RPC 1 |
Extent of monopoly must correspond to technical contribution; sufficiency requires enabling disclosure across claim breadth. |
Distinguished: the earlier case involved a complex product-by-process claim; here the claim is to a single chemical product fully enabled by the description. |
| Synthon BV v SmithKline Beecham Plc [2006] RPC 10 |
Test for novelty: prior disclosure must enable inevitable infringement. |
Used (at earlier stages) to confirm escitalopram was novel despite prior disclosure of the racemate. |
| Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9 |
Distinction between product, process and product-by-process claims; alignment with EPC principles. |
Cited to support consistency with EPO jurisprudence and to explain why product claims do not import process limitations. |
| Asahi Kasei Kogyo KK’s Application [1991] RPC 485 |
“Support” under s 14(5)(c) requires an enabling disclosure. |
Relied on to show that once an enabling disclosure for the product exists, additional process disclosures are unnecessary. |
| Exxon/Fuel Oils (T 409/91) [1994] OJEPO 653 |
EPO statement that claim scope should correspond to technical contribution. |
Court held this principle is satisfied because the technical contribution is the product itself. |
| Grain-Orientated Silicon Sheet/Kawasaki (T 595/90) [1994] OJEPO 695 |
Otherwise obvious product may be patentable if no known method previously existed to make it. |
Cited as direct EPO support for allowing broad product claims when the first inventive method is disclosed. |
Court's Reasoning and Analysis
1. Statutory Framework. The court examined sections 1, 14 and 72 of the Patents Act 1977 alongside Articles 52, 83 and 84 EPC. Section 14(3) requires an enabling disclosure; section 14(5)(c) requires claims be supported by the description.
2. Novelty and Inventive Step Undisputed. Escitalopram was accepted as novel and non-obvious; those findings were not appealed.
3. Nature of the Claim. The product claims cover a single chemical compound. The specification teaches at least one way (the diol route) to make that compound; therefore the product can be “performed” by the skilled person.
4. Sufficiency Test. For a product claim, sufficiency turns on the ability to make the product, not on disclosing every potential manufacturing route. The statutory requirement does not impose a second “novelty” hurdle under s 14(5)(c).
5. Technical Contribution. The technical contribution is the provision of the isolated (+) enantiomer itself. Aligning with consistent EPO authority, that contribution justifies a monopoly over the product irrespective of later-developed, independent processes.
6. Distinguishing Biogen. Biogen concerned a hybrid product-by-process claim covering multiple embodiments; its reasoning does not govern a simple single-compound product claim. Consequently, Judge Kitchin’s reliance on Biogen was misplaced.
7. Policy and International Consistency. The court emphasised the need to avoid divergence from EPO jurisprudence and noted that no EPO decision had ever invalidated a comparable product claim for the insufficiency reason advanced by the Appellants.
Holding and Implications
APPEAL DISMISSED. The court affirmed that the product claims to the isolated (+) enantiomer are not invalid for insufficiency; the patent remains in force.
Implications: The decision confirms that, under United Kingdom law aligned with EPC principles, a patentee who first makes a novel chemical product is entitled to claim that product broadly, even if only one inventive manufacturing method is disclosed. The ruling safeguards certainty for innovators and harmonises national doctrine with established EPO practice without creating new precedent beyond that alignment.